Objective:To investigate the effects of oral propranolol on the heart rate and blood glucose levels in children with hemangiomas receiving hospital care.Methods:A total of 259 children [77 males and 182 females, aged (125.2±85.4) days, weighted (6.3±1.6) kg], who were treated with oral propranolol for the first time under hospital care from January 2013 to August 2021, were retrospectively analyzed. After fasting, the patients administered the same dose of propranolol once daily (0.5-2.5 mg/kg). Fasting blood glucose and heart rate were measured in all children before propranolol administration and after 2 h. Heart rate was measured at 1, 3 and 6 h after propranolol administration for three consecutive days. Adverse reactions were observed and recorded.Results:Within three days of oral propranolol administration, the heart rates at 1, 3 and 6 h after propranolol administration were lower than those before propranolol administration (all P<0.001). Within three days after taking propranolol and 2 h after taking propranolol daily, blood glucose levels reduced in all children (all P<0.001). During the hospitalization period, the incidence of adverse reactions was 5.4% (14/259), including lesion ulcers in four cases, upper respiratory tract infection with fever in four, reduced eating in two, nausea and vomiting in one, lethargy in one, sinus tachycardia in one, and hyperkalemia in one. No serious adverse reactions were life-threatening. Conclusion:After oral administration of propranolol, the heart rate and blood sugar of the children decrease to different degrees compared with those before propranolol administration.

Objective:To investigate the effects of oral propranolol on the heart rate and blood glucose levels in children with hemangiomas receiving hospital care.Methods:A total of 259 children [77 males and 182 females, aged (125.2±85.4) days, weighted (6.3±1.6) kg], who were treated with oral propranolol for the first time under hospital care from January 2013 to August 2021, were retrospectively analyzed. After fasting, the patients administered the same dose of propranolol once daily (0.5-2.5 mg/kg). Fasting blood glucose and heart rate were measured in all children before propranolol administration and after 2 h. Heart rate was measured at 1, 3 and 6 h after propranolol administration for three consecutive days. Adverse reactions were observed and recorded.Results:Within three days of oral propranolol administration, the heart rates at 1, 3 and 6 h after propranolol administration were lower than those before propranolol administration (all P<0.001). Within three days after taking propranolol and 2 h after taking propranolol daily, blood glucose levels reduced in all children (all P<0.001). During the hospitalization period, the incidence of adverse reactions was 5.4% (14/259), including lesion ulcers in four cases, upper respiratory tract infection with fever in four, reduced eating in two, nausea and vomiting in one, lethargy in one, sinus tachycardia in one, and hyperkalemia in one. No serious adverse reactions were life-threatening. Conclusion:After oral administration of propranolol, the heart rate and blood sugar of the children decrease to different degrees compared with those before propranolol administration.

Objective:To summarize the relationship between the clinicopathological features and prognosis of immunoglobulin A nephropathy (IgAN) after renal transplantation.Methods:A total of 34 patients with IgAN after renal transplantation confirmed by renal biopsy were enrolled. And another 34 patients with primary IgAN confirmed by initial renal biopsy were adopted as controls. Clinical and pathological features of two groups were compared to explore the relationship between clinicopathological features and prognosis of allograft IgAN.Results:As compared with primary IgAN group, renal function in allograft IgAN group included serum creatinine [(158.5±75.9) vs (84.8±26.8) umol/L], urea nitrogen [(9.7±6.1) vs (5.2±1.4) mmol/L], uric acid [(406.7±87.8) vs (359.0±92.6) umol/L], estimated glomerular filtration rate {(57.4±25.4) vs (91.2±28.6) [ml/(min·1.73m 2)]}. All were statistically significantly higher ( P<0.05) while other parameters showed no differences. Pathologically, the proportion of T1 type (50.0% vs 17.6%) of renal tubular atrophy/interstitial fibrosis was significantly higher in allograft IgAN group than control group ( P<0.05). Furthermore, univariate and multivariate Logistic regression analyses were performed between various pathological parameters and prognosis in allograft IgAN patients. It indicated that the degree of mesangial hyperplasia of patients with transplanted IgAN had a significantly negative impact on the prognosis. Conclusions:The clinicopathological features of patients with allograft IgAN show no difference from those of patients with primary IgAN. And among patients with allograft IgAN, those with severe mesangial hyperplasia often have a worse prognosis.